Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CytRx Picks Up Four Clinical-Stage Oncology Candidates With Innovive Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Biopharma separately plans additional toxicology tests for ALS candidate arimoclomal to address clinical hold imposed by FDA.

You may also be interested in...



CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol

CytRx, which has bet heavily on oncology since FDA put a hold on the CNS drug, plans to resume partnering talks for arimoclomol as it restarts the trial.

CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol

CytRx, which has bet heavily on oncology since FDA put a hold on the CNS drug, plans to resume partnering talks for arimoclomol as it restarts the trial.

CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol

CytRx's potentially disease-altering approach for neurological disorders got a new lease on life after FDA accepted a revised trial protocol and said the company could continue its Phase IIb trial in amyotrophic lateral sclerosis (Lou Gehrig's disease) patients, the firm announced Dec. 2

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel